|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 95.35 USD | +3.36% |
|
+6.36% | +147.02% |
| Capitalization | 5.96B 5.08B 4.74B 4.46B 8.22B 540B 8.98B 55.37B 21.48B 254B 22.37B 21.89B 929B | P/E ratio 2025 * |
-59.8x | P/E ratio 2026 * | 95.7x |
|---|---|---|---|---|---|
| Enterprise value | 5.77B 4.92B 4.59B 4.32B 7.96B 523B 8.69B 53.62B 20.8B 246B 21.66B 21.2B 899B | EV / Sales 2025 * |
86.4x | EV / Sales 2026 * | 20.5x |
| Free-Float |
95.31% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Protagonist Therapeutics, Inc.
| 1 day | +3.36% | ||
| 1 week | +6.36% | ||
| Current month | +5.94% | ||
| 1 month | +12.37% | ||
| 3 months | +61.99% | ||
| 6 months | +69.30% | ||
| Current year | +147.02% |
| 1 week | 88.3 |  | 95.39 |
| 1 month | 82.06 | | 95.39 |
| Current year | 33.7 | | 95.39 |
| 1 year | 33.7 | | 95.39 |
| 3 years | 8.4 | | 95.39 |
| 5 years | 6.91 | | 95.39 |
| 10 years | 4.47 | | 95.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 68 | 2008-11-30 |
Asif Ali
DFI | Director of Finance/CFO | 51 | 2022-04-17 |
Newman Yeilding
CTO | Chief Tech/Sci/R&D Officer | - | 2025-01-01 |
| Director | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
BRD | Director/Board Member | 68 | 2008-11-30 |
Harold Selick
CHM | Chairman | 70 | 2014-03-18 |
William Waddill
BRD | Director/Board Member | 68 | 2016-06-30 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.36% | +6.36% | +136.13% | +1,119.31% | 5.96B | |
| -1.79% | -5.23% | -6.09% | +11.09% | 45.43B | |
| -1.65% | -1.59% | +10.92% | +4.28% | 37.85B | |
| -0.55% | -1.19% | +76.99% | +56.17% | 35.31B | |
| +0.05% | +1.91% | +10.32% | +20.20% | 27.66B | |
| -1.46% | +1.78% | +60.58% | +164.03% | 15.72B | |
| +0.52% | -0.90% | +75.65% | +231.60% | 15.26B | |
| -1.76% | +0.38% | -11.49% | -5.32% | 14.25B | |
| -4.40% | -7.89% | +68.16% | - | 12.56B | |
| +4.88% | +7.29% | +68.72% | +79.89% | 13.47B | |
| Average | -0.05% | -0.11% | +48.99% | +186.81% | 22.35B | |
| Weighted average by Cap. | -0.64% | -1.29% | +34.35% | +80.57% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 66.81M 56.91M 53.16M 50.02M 92.09M 6.05B 101M 621M 241M 2.85B 251M 245M 10.41B | 273M 233M 218M 205M 377M 24.77B 412M 2.54B 985M 11.68B 1.03B 1B 42.6B |
| Net income | -102M -86.96M -81.23M -76.43M -141M -9.25B -154M -948M -368M -4.36B -383M -375M -15.9B | 29.94M 25.51M 23.83M 22.42M 41.27M 2.71B 45.09M 278M 108M 1.28B 112M 110M 4.66B |
| Net Debt | -188M -161M -150M -141M -260M -17.07B -284M -1.75B -679M -8.05B -707M -692M -29.36B | -353M -301M -281M -264M -487M -31.98B -532M -3.28B -1.27B -15.07B -1.32B -1.3B -55B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 95.35 $ | +3.36% | 1,287,130 |
| 25-12-11 | 92.25 $ | +0.95% | 800,761 |
| 25-12-10 | 91.38 $ | +3.18% | 1,308,400 |
| 25-12-09 | 88.56 $ | -1.87% | 1,440,173 |
| 25-12-08 | 90.25 $ | +0.67% | 1,455,768 |
Delayed Quote Nasdaq, December 12, 2025 at 04:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PTGX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition